Short answer
Celcuity Inc. (CELC) filed an 8-K current report with the SEC on July 15, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). FDA approval of REVTORPYK (gedatolisib) for HR+/HER2- advanced or metastatic breast cancer.
Celcuity Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- FDA approval of REVTORPYK (gedatolisib) for HR+/HER2- advanced or metastatic breast cancer
- Indication covers patients without detected PIK3CA mutations after progression on endocrine therapy
- Approval enables commercial launch in a defined breast cancer population
- Company webcast and presentation provided additional approval details on July 14, 2026
Item 8.01 · Other Events
- FDA approval for REVTORPYK in HR+/HER2- advanced or metastatic breast cancer without detected PIK3CA mutation
- Commercial launch targeted for late Q3 2026, shifting Celcuity toward revenue generation and commercialization execution
- Supplemental NDA planned for Q3 2026 targeting PIK3CA-mutated disease, expanding potential addressable indications
- sNDA submission based on mutant cohort results from the Phase 3 VIKTORIA-1 trial
Item EX-99.1 · Exhibit EX-99.1
- FDA approval makes REVTORPYK Celcuity’s first commercial product for HR+/HER2-, PIK3CA wild-type advanced breast cancer
- VIKTORIA-1 triplet reduced progression or death risk 76%, with median PFS 9.3 months versus 2.0 months
- Doublet reduced progression or death risk 67%, with median PFS 7.4 months versus 2.0 months
- Commercial launch targeted for late Q3 2026, creating near-term execution and market-access catalysts
- sNDA submission planned in Q3 2026 for PIK3CA-mutated disease, potentially expanding the eligible market beyond the initial indication
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Celcuity Inc. 8-K filings
Get the next CELC 8-K as it lands
Follow CELC for push alerts, or ask the research agent what this filing means.